[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655352":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":30,"studyPopulation":31,"armGroups":32,"interventions":26,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":42,"collaborators":26,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":26,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":26,"enrollmentInfo":56,"targetDuration":26,"studyType":59,"phases":26,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":69,"whyStopped":26,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":26},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":26},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Plasma Concentration of Glial Fibrillary Acidic Protein (GFAP)main outcome","Measured in picograms per milliliter (pg\u002FmL) via automated chemiluminescent immunoassay (Lumipulse or Alinity platform) or ELISA, from venous blood collected in EDTA tubes","Baseline (single time point)",{"measure":14,"description":15,"timeFrame":12},"Hippocampal Volume on MRI, Whole-Brain Volume on MRI,Ventricular Volume on MRI","Measured in cubic millimeters (mm³), normalized to total intracranial volume, derived from 3-Tesla 3D T1-weighted MPRAGE MRI using automated segmentation software (FreeSurfer)",{"measure":17,"description":18,"timeFrame":12},"EEG Band Power Alpha , beta , delta , theta","Absolute spectral power (µV²) in the different frequency band , derived from resting-state EEG recorded with a 19-channel 10-20 electrode montage",[20,23],{"measure":21,"description":22,"timeFrame":12},"Correlation Between Plasma GFAP and MRI Volumetric Measures Across Dementia Etiological Subtypes","Pearson\u002FSpearman correlation coefficient between plasma GFAP concentration (pg\u002FmL) and MRI-derived regional brain volumes (mm³), calculated separately within Alzheimer's, vascular, Lewy body, frontotemporal, and mixed dementia subgroups",{"measure":24,"description":25,"timeFrame":12},"Correlation Between Plasma GFAP and EEG Spectral Power Measures Across Dementia Etiological Subtypes","Pearson\u002FSpearman correlation coefficient between plasma GFAP concentration (pg\u002FmL) and EEG band power (µV²), calculated separately within Alzheimer's, vascular, Lewy body, frontotemporal, and mixed dementia subgroups",null,{"allocation":26,"interventionModel":26,"interventionModelDescription":26,"primaryPurpose":26,"observationalModel":28,"timePerspective":29,"maskingInfo":26},"CASE_CONTROL","RETROSPECTIVE","This is a cross-sectional, observational, case-control study designed to characterize and compare plasma glial fibrillary acidic protein (GFAP), quantitative electroencephalography (EEG), and MRI-based brain volumetry across three groups: healthy controls, participants with mild cognitive impairment (MCI), and participants with dementia of any etiology (Alzheimer's, vascular, Lewy body, frontotemporal, or mixed).\n\nPlasma GFAP, an astrocytic activation marker, will be quantified from EDTA-collected blood via automated chemiluminescent immunoassay (Lumipulse or Alinity platform where available) or conventional ELISA. Structural brain volumetry (hippocampal, medial temporal, and whole-brain\u002Fventricular volumes) will be derived from 3-Tesla MRI using a 3D T1-weighted MPRAGE sequence with automated segmentation. Resting-state EEG will be recorded using a 19-channel 10-20 electrode montage for quantitative spectral power analysis across standard frequency bands.\n\nAll participants will undergo a standardized clinical and psychometric assessment, including the Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), and functional assessment via the Katz Index and Lawton-Brody Instrumental Activities of Daily Living scale, to confirm group classification prior to biomarker collection.\n\nThe study addresses a gap in the literature: although plasma GFAP, MRI volumetry, and EEG have each been separately validated as markers of neurodegeneration, few studies have jointly acquired all three modalities within a single cohort spanning the full continuum from normal cognition through dementia, and fewer still have done so in an Egyptian or broader Middle East\u002FNorth Africa population across all dementia etiologies rather than Alzheimer's disease alone. Findings from this study are intended to inform the development of a combined biomarker panel for earlier and more accurate differentiation between normal cognitive aging, MCI, and dementia.","The study will include three groups matched for age, sex and educational level: from Outpatient clinic of the Department of Neurology and Psychiatry, Assiut University Hospitals healthy controls, patients with mild cognitive impairment (MCI), and patients with dementia of any etiology (Alzheimer's, vascular, Lewy body, frontotemporal and mixed dementia)",[33,36,39],{"label":34,"type":26,"description":35,"interventionNames":26},"Dementia","according toDSM -5 , with a total Mini-Mental State Examination score \\\u003C 24 (or \\\u003C 22 according to educational state), together with a Modified Mini-Mental State Examination (3MS) score \\\u003C 79 to confirm cognitive impairment",{"label":37,"type":26,"description":38,"interventionNames":26},"Mild Cognitive impairment","impairment diagnosed according to established diagnostic criteria",{"label":40,"type":26,"description":41,"interventionNames":26},"control","healthy group matched age, sex",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Abdelrahman Goda","Assistant lecturer","100655352","multimodal-biomarkers-in-individual-with-cognitive-impairment-and-dementia-100655352",false,"NCT07812480","Multimodal Biomarkers in Individual With Cognitive Impairment and Dementia","Multimodal Biomarkers in Individual With Cognitive Impairment and Dementia: A Case Control Study","Inclusion Criteria:\n\n1. Dementia diagnosed according to DSM -5\\\\ with a total Mini-Mental State Examination score \\\u003C 24 (or \\\u003C 22 according to educational state), together with a Modified Mini-Mental State Examination (3MS) score \\\u003C 79 to confirm cognitive impairment.\n2. Mild cognitive impairment diagnosed according to established diagnostic criteria according to DSM -5.\n3. Men or women of at least 50 years of age.\n4. Reliable in individual data and willing to make themselves available for the duration of the study.\n5. Clear written informed consent obtained from a first-degree relative for each patient participant, and from the control participant himself\u002Fherself.\n\nExclusion Criteria:\n\n* age below 50 years .\n\n  * other neurological disorders or psychiatric disorders; previous history of stroke; metabolic disturbance; other major medical illnesses; epilepsy; inflammatory, autoimmune, or infectious disease; metallic objects in the body; craniotomy in the past.\n  * Presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study\n  * MRI contraindication (pacemaker, metallic implants, severe claustrophobia).",true,"ALL","50 Years",{"count":57,"type":58},75,"ESTIMATED","OBSERVATIONAL","Memory problems can range from normal aging to mild cognitive impairment (MCI) to dementia. This study looks at three ways of measuring what is happening in the brain at each of these stages: a blood test (GFAP), a brain MRI scan, and a brain wave test (EEG). The goal is to see whether combining these three tests can help doctors tell the difference between normal aging, MCI, and dementia more accurately, and whether this approach works well in an Egyptian population, including all common causes of dementia (not only Alzheimer's disease).\n\nAdults aged 50 to 85 will be placed into one of three groups: those with normal memory, those with mild memory problems (MCI), and those with dementia. Everyone will have a memory and thinking assessment, a blood draw, a brain MRI, and a brain wave (EEG) recording. No new medication or treatment is given as part of this study; it involves only assessment and testing. The information gathered may help doctors diagnose memory problems earlier and more accurately in the future.",[62,63],"Dementia Disorders","Mild Cognitive Impairment (MCI)",[65,66,67,68],"dementia","cognition","mild cognitive impairment","GFAP","NOT_YET_RECRUITING","2026-09-04",{"date":72,"type":73},"2026-09-10","ACTUAL",{"date":75,"type":58},"2026-10-10",{"date":77,"type":58},"2029-03-10",{"name":5,"class":6}]